Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility StudyLaetitia E. Lamberts, Gooitzen M. van Dam, Maximillian Koch et al.|Clinical Cancer Research|2016Cited by 289
Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast CancerMaximilian Koch, Vasilis Ntziachristos, Johannes S. de Jong et al.|Cancer Research|2016Cited by 43
Supplemental Materials and Methods and Supplementary Figures 1 and 2 from Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast CancerMaximilian Koch, Vasilis Ntziachristos, Johannes S. de Jong et al.|Unknown|2023Cited by 0
Supplemental Materials and Methods and Supplementary Figures 1 and 2 from Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast CancerMaximilian Koch, Vasilis Ntziachristos, Johannes S. de Jong et al.|Unknown|2023Cited by 0
Data from Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast CancerMaximilian Koch, Vasilis Ntziachristos, Johannes S. de Jong et al.|Unknown|2023Cited by 0